national stem-cell therapy logo

Breakthrough in Alzheimer’s Treatment: Lomecel-B™ Receives RMAT Designation from FDA

Longeveron logo

Longeveron Inc., a clinical stage regenerative medicine biotechnology company, has achieved a significant milestone in the fight against Alzheimer’s Disease. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Lomecel-B™ for the treatment of mild Alzheimer’s Disease. This designation underscores the potential of Lomecel-B™ to provide a new […]

Revolutionary Cell Therapy Shows Promise: Over 90% Seizure Reduction in Drug-Resistant Epilepsy Patients

Neurona Therapeutics logo

Neurona Therapeutics, a clinical-stage biotherapeutics company, is developing regenerative cell therapies for the treatment of neurological disorders. They recently presented updated clinical data from their ongoing Phase I/II trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) at the American Academy of Neurology 2023 Annual Meeting. The data showed a >90% reduction […]

Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data

Neurona Therapeutics logo

SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer, was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical […]